Skip to content
Search
Facebook
 
ADCSADCS
ADCS
Alzheimer's Disease Cooperative Study
  • About Us
    • About ADCS
    • Meet the Directors
    • ADCS Cores
    • ADCS Clinical Trials Network
    • Steering Committee Voting Members
  • Public & Participant Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Clinical Sites
    • Types of Studies
    • Clinical Trials
    • Study Newsletters
    • Research News
    • Alzheimer’s Study Quilt Project
  • Investigator Resources
    • Publications
    • Study Resources
    • Data Sharing
    • Biospecimen Bank
    • ADCS Instruments
    • Proposal Submission
  • CTMS
    • Clinical Conductor Enterprise
    • Clinical Conductor Site Portals
  • Donate
  • Steering Committee Members
  • Staff Resources
  • About Us
    • About ADCS
    • Meet the Directors
    • ADCS Cores
    • ADCS Clinical Trials Network
    • Steering Committee Voting Members
  • Public & Participant Resources
    • About Alzheimer’s Disease
    • AD Resources
    • Clinical Sites
    • Types of Studies
    • Clinical Trials
    • Study Newsletters
    • Research News
    • Alzheimer’s Study Quilt Project
  • Investigator Resources
    • Publications
    • Study Resources
    • Data Sharing
    • Biospecimen Bank
    • ADCS Instruments
    • Proposal Submission
  • CTMS
    • Clinical Conductor Enterprise
    • Clinical Conductor Site Portals
  • Donate
  • Steering Committee Members
  • Staff Resources

Vitamin E in Mild to Moderate AD: Can we slow down functional deterioration?

You are here:
  1. Home
  2. Research News
  3. Vitamin E in Mild to…

Although vitamin E and memantine have been shown to have beneficial effects in moderately severe Alzheimer disease (AD), evidence is limited in mild to moderate AD.

Post navigation

PreviousPrevious post:A new online report from the National Institutes of Health (NIH) highlights recent progress in NIH-supported Alzheimer’s disease research.NextNext post:In the largest-ever genetic analysis conducted on Alzheimer’s disease, an international group of researchers has identified 11 new genes associated with the disorder, doubling the number of known gene variants linked to it.
About ADCS
The Alzheimer’s Disease Cooperative Study (ADCS) was formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California San Diego.
Contact Us
  • E-mail:
    alzinfo@ucsd.edu
  • Phone:
    858-246-1333

Find us on:

FacebookRssMail
Location
Shipping Address:
9452 Medical Center Drive
4th Floor
La Jolla, CA 92037

Mailing Address:
9500 Gilman Dr
MC0949
La Jolla, CA 92093-0949
ADCS
Copyright 2017 Regents of the University of California.